How clinical trials work

The pathway that
takes us to tomorrow’s breakthroughs

Clinical trials help us learn more about ways to prevent or treat medical conditions. Research must show a study medicine is safe and effective before it can be approved for use. Without these clinical research studies and the volunteers who take part in them, modern medicine would not exist.

We first test a study vaccine or study medicine with a small group of clinical trial participants to understand its safety. If the safety is acceptable, we then test the study vaccine or study medicine with a larger group of people to understand the efficacy and continue to look at safety. This series of clinical trials unfolds across four main phases.

The four phases of clinical trials

As a participant in a phase 1 clinical trial, you’ll help researchers understand the safety of a study medicine. You may have frequent clinical exams and lab work, and will be asked to report any issues or side effects.

20-100 participants
1 week to several months

By joining a phase 2 clinical trial, you’re helping researchers better understand how well the study medicine may work for the condition being studied, and the side effects that may occur.  

As many as several hundred participants

1-2 years on average

In a phase 3 clinical trial, you’ll be part of a larger group of people with the medical condition being studied. Your participation helps researchers determine whether the study medicine is safe and effective for people with that condition.

Several hundred to several thousand participants

1-4 years on average

Even after medicines are approved for use, you can continue to participate in long-term clinical studies designed to better understand the effects of the approved medicine over time.  

Typically several thousand participants

More than a year

As a participant in a phase 1 clinical trial, you’ll help researchers understand the safety of a study medicine. You may have frequent clinical exams and lab work, and will be asked to report any issues or side effects.

20-100 participants
1 week to several months

By joining a phase 2 clinical trial, you’re helping researchers better understand how well the study medicine may work for the condition being studied, and the side effects that may occur.  

As many as several hundred participants

1-2 years on average

In a phase 3 clinical trial, you’ll be part of a larger group of people with the medical condition being studied. Your participation helps researchers determine whether the study medicinenis safe and effective for people with that condition.

Several hundred to several thousand participants

1-4 years on average

Even after medicines are approved for use, you can continue to participate in long-term clinical studies designed to better understand the effects of the approved medicine over time.  

Typically several thousand participants

More than a year

En tant que participant(e) à un essai clinique de phase I, vous aiderez les chercheurs à comprendre l’innocuité d’un médicament à l’étude. Vous serez soumis(e) à des examens cliniques et de laboratoire fréquents, et il vous sera demandé de signaler tout problème ou effet indésirable.
En participant à un essai clinique de phase II, vous aidez les chercheurs à mieux comprendre l’efficacité du médicament à l’étude pour l’affection étudiée, ainsi que les effets indésirables qui peuvent survenir.
Dans un essai clinique de phase III, vous ferez partie d’un groupe plus important de personnes atteintes de la maladie étudiée. Votre participation permet aux chercheurs de déterminer si le médicament à l’étude est sûr et efficace pour les personnes atteintes de cette affection.
Même après l’autorisation d’utilisation des médicaments, vous pouvez continuer à participer à des études cliniques à long terme destinées à mieux comprendre les effets du médicament autorisé dans le temps.
20–100 participants
1 semaine à plusieurs mois
Jusqu’à plusieurs centaines de participants
1–2 ans en moyenne
Plusieurs centaines à plusieurs milliers de participants
1–4 ans en moyenne
Généralement, plusieurs milliers de participants
Plus d’un an
Als deelnemer aan een fase-1 klinisch onderzoek helpt u onderzoekers de veiligheid van een onderzoeksgeneesmiddel te begrijpen. Er worden mogelijk regelmatig klinische tests en laboratoriumtests uitgevoerd en u wordt gevraagd om problemen of bijwerkingen te melden.
Door deel te nemen aan een fase-2 klinisch onderzoek, helpt u onderzoekers beter begrijpen hoe goed het onderzoeksgeneesmiddel kan werken voor de aandoening die wordt onderzocht, evenals welke bijwerkingen kunnen optreden.
In een fase-3 klinisch onderzoek maakt u deel uit van een grotere groep mensen met de medische aandoening die wordt onderzocht. Uw deelname helpt onderzoekers vast te stellen of het onderzoeksgeneesmiddel veilig en werkzaam is voor mensen met die aandoening.
Zelfs nadat geneesmiddelen zijn goedgekeurd voor gebruik, kunt u blijven deelnemen aan klinische onderzoeken voor de lange termijn, die zijn opgezet om de gevolgen van het goedgekeurde geneesmiddel gedurende een langere periode beter te begrijpen.
20-100 deelnemers
1 week tot meerdere maanden
Tot wel meerdere honderden deelnemers
Gemiddeld 1-2 jaar
Meerdere honderden tot meerdere duizenden deelnemers
Gemiddeld 1-4 jaar 
Gewoonlijk meerdere duizenden deelnemers
Meer dan een jaar
As a participant in a phase 1 clinical trial, you’ll help researchers understand the safety of a study medicine. You may have frequent clinical exams and lab work, and will be asked to report any issues or side effects.
By joining a phase 2 clinical trial, you’re helping researchers better understand how well the study medicine may work for the condition being studied, and the side effects that may occur.
In a phase 3 clinical trial, you’ll be part of a larger group of people with the medical condition being studied. Your participation helps researchers determine whether the study medicine is safe and effective for people with that condition.
Even after medicines are approved for use, you can continue to participate in long-term clinical studies designed to better understand the effects of the approved medicine over time.
20-100 participants
1 week to several months
As many as several hundred participants
1-2 years on average
Several hundred to several thousand participants
1-4 years on average
Typically several thousand participants
More than a year
Study medicine is approved by regulatory authorities.
Submission
Review
Approval
Available
to patients
Onderzoeksgeneesmiddel wordt goedgekeurd door regelgevende instanties.
Indiening
Beoordeling
Goedkeuring
Beschikbaar
voor
patiënten 

How clinical trials are designed

Protocol

Clinical trials start with a protocol. A clinical trial protocol is a detailed plan that explains the purpose of the clinical trial and how it will be run. It includes:

the length of the clinical trial

information about who can participate

the study medicines, procedures, and tests in the clinical trial

how side effects will be tracked, managed, and reported

the schedule of study activities

the rules that must be followed

The protocol will also describe whether the clinical trial:
  • uses randomisation
  • is controlled
  • uses blinding

Randomisation

Participants are assigned to different treatment groups in a clinical trial by a process called randomisation. Randomisation means that participants are assigned to a treatment group by chance (like flipping a coin) rather than by choice.

 

Randomisation is one way to help avoid bias in a study. For example, it helps ensure that people of the same sex or age are not all assigned to the same treatment group.

Controlled trial

A controlled trial is a clinical trial that includes a comparison (control) group. In controlled clinical trials, participants are put into groups that receive the study medicine or a ‘comparator.’ We learn about the effectiveness and safety of the study medicine by comparing the experiences of the participants who receive the study medicine with those who receive the comparator.

 

A common example of a comparator is ‘standard of care,’ the established treatment that is currently used for a condition.

 

In a ‘double blind’ controlled trial, placebos are used to prevent the participant and study team from knowing whether the participant is receiving the study medicine or the comparator. A placebo does not contain any active ingredients, but the study medicine and placebo look alike. Learn more about single-blind and double-blind trials below.

Participants

A computer randomly assigns each participant to one of two or more groups to prevent bias

Investigational group receives study medicine

Control group receives comparatur

Single-blind or double-blind clinical trials

Clinical trials could be single-blind or double-blind.


In a single-blind trial, the participants do not know whether they are receiving the study medicine or placebo, but the researchers know.


In double-blind trials, neither the participants nor the researchers know whether the participants are receiving the study medicine or placebo. (If necessary, such as for a safety reason, the researchers can find out what a participant has received.)


Clinical trials use blinding to help prevent bias. This way, the awareness of which treatment group a participant is in does not influence the participant or the study team.


All clinical trials are ‘unblinded,’ either after they are complete or when blinding is no longer necessary. When a study is unblinded, the assigned treatment group for each participant is revealed.

Estudios clínicos de enmascaramiento simple o doble

Clinical trials could be single-blind or double-blind.


In a single-blind trial, the participants do not know whether they are receiving the study medicine or placebo, but the researchers know.


In double-blind trials, neither the participants nor the researchers know whether the participants are receiving the study medicine or placebo. (If necessary, such as for a safety reason, the researchers can find out what a participant has received.)


Clinical trials use blinding to help prevent bias. This way, the awareness of which treatment group a participant is in does not influence the participant or the study team.


All clinical trials are ‘unblinded,’ either after they are complete or when blinding is no longer necessary. When a study is unblinded, the assigned treatment group for each participant is revealed.

About 

MagnetisMM  

Steps to join

a clinical trial

Protecting 

your safety 

& privacy   

FAQ’s

en_USEN-AU